Skip to main content

Month: April 2020

Asure Announces COVID-19 Resource Center to help SMBs Survive the Pandemic and Rebound in Growth Faster

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) — Asure Software (NASDAQ:ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, announces its COVID-19 Resource Center focused on helping small and medium-sized businesses (SMBs) survive and rebound in the aftermath of the pandemic. The resource center includes the latest tools and information for navigating new state and federal legislation, such as the Coronavirus Aid, Relief and Economic Security Act (CARES Act) and the Families First Coronavirus Response Act (FFCRA), free payroll cards, free access, for current customers, to Asure’s HR live support and HR library, and more.“We know small and medium sized businesses are working exceptionally hard right now as they face a wave of new challenges every day due to effects of COVID-19,” said Pat Goepel,...

Continue reading

LAURENT-PERRIER : Déclaration mensuelle des droits de vote au 31.03.2020

Laurent-PerrierSociété anonyme à Directoire et Conseil de Surveillanceau capital de 22.594.271,80 eurosSiège Social : 32, avenue de Champagne 51150 Tours-sur-MarneRCS Reims B 335 680 096Informations relatives au nombre total de droits de vote et d’actions composant le capital socialArticle L 233-8 II du Code de commerce et l’article 223-16 du Règlement Général del’Autorité des Marchés FinanciersLaurent-Perrier est l’un des rares groupes de maisons de champagne cotés en Bourse, qui soient dédiés exclusivement au champagne et focalisés sur le haut de gamme. Il dispose d’un large portefeuille de produits renommés pour leur qualité, autour des marques Laurent-Perrier, Salon, Delamotte et Champagne De Castellane.Pièce jointeLaurent-Perrier – Déclaration Mensuelle des droits de vote

Continue reading

COLLIERS INTERNATIONAL APPOINTS JANE GAVAN TO BOARD OF DIRECTORS

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Leading global commercial real estate services and investment management firm Colliers International (NASDAQ and TSX: CIGI) announced the appointment of Ms. P. Jane Gavan to its Board of Directors, effective immediately.Ms. Gavan is President, Asset Management of Dream Unlimited, one of Canada’s leading real estate companies with approximately $9 billion of assets under management in North America and Europe. She brings more than 30 years of experience in the real estate industry, having held increasingly senior positions since joining Dream. She served as Chief Executive Officer of Dream Global Real Estate Investment Trust, a TSX listed real estate investment income trust (REIT) from its 2011 IPO until its sale to Blackstone in December 2019.Prior to joining Dream, Ms. Gavan acted as legal...

Continue reading

Tauriga Sciences, Inc. Reports 250%+ Sequential Quarter to Quarter Revenue Growth in its E-Commerce Business Segment

NEW YORK, NY, April 08, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that its E-Commerce business segment experienced strong revenue growth, during its most recent completed quarter — 4th Fiscal Quarter 2020 (period: January 1, 2020 – March 31, 2020).  On a sequential Quarter to Quarter basis, the Company reported revenue growth in excess of 250% with a corresponding spike in both individual transactions and visitor traffic on its E-Commerce platform (www.taurigum.com).    In other news, the Company expects to receive its Cannabigerol...

Continue reading

Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects

Highlights:Phase I trial agreement with leading clinical research organizationHuman safety and tolerability study to assess infusion of RECCE® 327 in 40 healthy subjects as a single ascending dose  Estimated start-to-completion with data read-outs less than 12 months from nowFirst patients expected to be dosed in second half of 2020SYDNEY, Australia, April 08, 2020 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of broad-spectrum synthetic antibiotics, today announced it has formalized a Phase I clinical trial agreement to conduct a first-in-human study of its lead compound RECCE® 327 in 40 healthy subjects.The Phase I clinical study of RECCE® 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system. This initiative seeks to...

Continue reading

KP Tissue to Release its Financial Results and those of Kruger Products L.P. for the First Quarter of 2020

MISSISSAUGA, Ontario, April 08, 2020 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX:KPT), which holds a limited partnership interest in Kruger Products L.P. (“KPLP”), will release the financial results for KPT and KPLP for the first quarter of 2020 on Friday, May 8 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time.Details of the Conference CallVia telephone: 1- 877-223-4471 or 647-788-4922Via the internet at: www.kptissueinc.comPresentation material referenced during the conference call will be available at www.kptissueinc.com.Conference Call RebroadcastA rebroadcast of the conference call will be available until midnight, May 15, 2020 by dialing 1-800-585-8367 or 416-621-4642 and entering passcode­­ 6936809.The replay of the webcast will remain available on the web site until midnight,...

Continue reading

Papiers Tissu KP publiera ses résultats financiers et ceux de Produits Kruger S.E.C. pour le premier trimestre de l’exercice 2020

MISSISSAUGA, Ontario, 08 avr. 2020 (GLOBE NEWSWIRE) — Papiers Tissu KP inc. (TSX : KPT) (« PTKP »), qui détient un intérêt limité dans Produits Kruger S.E.C (« PK S.E.C. »), publiera les résultats financiers de PTKP et de PK S.E.C. pour le premier trimestre de l’exercice 2020 le vendredi 8 mai 2020, avant l’ouverture de la séance. PTKP tiendra une téléconférence cette même journée, à 8 h 30, heure de l’Est.Renseignements sur la téléconférence (en anglais seulement)Au téléphone : 1- 877-223-4471 ou 647-788-4922Sur le site Web : www.kptissueinc.comLes documents auxquels on fera référence lors de la téléconférence seront disponibles au www.kptissueinc.com.Téléconférence archivéeLa téléconférence sera disponible jusqu’à minuit le 15 mai 2020 et il sera possible d’y accéder en composant le 1-800-585-8367 ou le 416-621-4642 et en...

Continue reading

Kura Sushi USA to Announce Second Quarter 2020 Financial Results on April 14, 2020

IRVINE, Calif., April 08, 2020 (GLOBE NEWSWIRE) — Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”), (NASDAQ: KRUS), a fast-growing technology-enabled Japanese restaurant concept, today announced that it will host a conference call to discuss second quarter 2020 financial results on Tuesday, April 14th, 2020 at 5:00 p.m. ET. A press release with second quarter 2020 financial results will be issued that same day after the market close.  Hosting the conference call and webcast will be Hajime “Jimmy” Uba, President and Chief Executive Officer, and Koji Shinohara, Chief Financial Officer.Interested parties may listen to the conference call via telephone by dialing 201-689-8471. A telephone replay will be available shortly after the call has concluded and can be accessed by dialing 412-317-6671; the passcode is 13701829.The webcast...

Continue reading

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada

MONTREAL, April 08, 2020 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in Canada are completed with expected public reimbursement to roll out in the respective provinces over the coming months.TH is the longest acting corticosteroid for intra articular injection, often lasting twice as long as competitive products. Health Canada previously approved TH in December 2017 for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis,...

Continue reading

MKS Instruments to Hold Virtual Annual Shareholder Meeting on New Date

ANDOVER, Mass., April 08, 2020 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that enable advanced processes and improve productivity, announced today that, due to the public health impact of the novel coronavirus (COVID-19) and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its shareholders and company personnel, it will change the date of its annual meeting of shareholders to Monday, May 11, 2020 and will hold this meeting via remote communication only. Shareholders will be able to participate in the annual meeting of shareholders only via the virtual meeting. As previously announced, the meeting will be held at 10:00 a.m. Eastern Time.As described in the proxy materials for the annual meeting of shareholders...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.